stockrow
Friday 6 November 2026
Export AEON’s income statement to Excel — free account
AEON Biopharma, Inc.
AEON Healthcare Biotechnology
- EPS
- +96.7%
- Free cash flow
- −76.9%
- Total debt
- −88.4%
Quarter to June 2026, against a year earlier
0.18
0.02
+12.50%
Follow AEON
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.54 | 0.99 | 0.49 | 0.90 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.58 | 0.79 | (5.75) | (4.50) | |
Debt/Assets |
0.00% | 17.87% | 622.30% | 195.23% | |
Debt/Equity |
0.00 | (0.09) | (0.63) | (0.86) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.20 | 0.22 | 0.13 | 0.57 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.07) | (0.06) | (0.47) | (0.22) | |
Cash per Share |
0.07 | 0.15 | 0.30 | 0.51 | |
Shareholders Equity per Share |
(0.30) | (0.41) | (5.55) | (1.71) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.30) | (0.41) | (5.55) | (1.71) | |
Free Cash Flow |
(3.70) | (2.64) | (4.71) | (2.60) | |
Working Capital |
(3.35) | (0.04) | (3.50) | (0.82) | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
(17.28) | (18.76) | (57.19) | (21.19) | |
| Other line items | |||||
Quick Ratio |
0.47 | 0.94 | 0.44 | 0.72 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.06) | (0.47) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.30 | 1.96 | 3.43 | 3.58 | |
Average Assets |
8.79 | 11.21 | 4.35 | 6.37 | |
Average Common Equity |
(15.61) | (14.04) | (41.80) | (25.98) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates